Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03146455
Other study ID # ThirdXiangyaHCSU
Secondary ID
Status Completed
Phase
First received May 7, 2017
Last updated March 24, 2018
Start date June 5, 2017
Est. completion date March 10, 2018

Study information

Verified date March 2018
Source The Third Xiangya Hospital of Central South University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study was to establish the normal reference range of Thrombelastogram parameters in Hunan by a multicenter study, and to analyze the specificity of Thrombelastogram detection and the influence of gender, age and blood type on Thrombelastogram. The study will provide basic data and statistical basis for the establishment of normal reference range of Thrombelastogram in Hunan.


Description:

Thrombelastograghy (TEG) is an important test to assess the blood coagulation function to monitor the whole process of perioperative coagulation. TEG can evaluate the coagulation cascade, from platelet aggregation, clot strengthening and fibrin cross-linking to eventually clot lysis in small volume of whole blood. The reference range is one important element to influence the TEG results. At present, a number of studies have shown that reference range of TEG exists significant differences between different racial and geographic. At the same time, reagent manufacturers also suggested that each TEG laboratory should establish its own reference range. So it is important to establish our own reference range of TEG to guide the clinical blood transfusion and treatment.


Recruitment information / eligibility

Status Completed
Enrollment 498
Est. completion date March 10, 2018
Est. primary completion date January 1, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

(1) 18< Age <65, and Han Chinese residents living in Hunan more than 3 years. (2) Health examination population who physical examination, assistant examination and serological examination were normal; Not suffer from other diseases last 3 months; Not take any medication last 7 days.

Exclusion Criteria:

1. Informed refusal. 2. Pregnancy, woman with menstrual period; volunteers who suffer from hematological system diseases such as hemorrhagic or thrombotic disease and take medicines that affect the function of blood coagulation (clopidogrel and aspirin, warfarin, rivaroxaban, dipyridamole, oral contraceptives, estrogen, antibiotics and traditional Chinese medicine related with blood coagulation, etc.) 3. Volunteers who have a history of liver disease, immune system disease, allergy and other disease within the last 3 months were excluded.

Study Design


Intervention

Other:
no intervention
no intervention

Locations

Country Name City State
China Third Xingya Hospital Changsha Hunan

Sponsors (5)

Lead Sponsor Collaborator
The Third Xiangya Hospital of Central South University Changsha Central Hospital, Hunan Cancer Hospital, Hunan Provincial People's Hospital, Second Xiangya Hospital of Central South University

Country where clinical trial is conducted

China, 

References & Publications (8)

Ak K, Isbir CS, Tetik S, Atalan N, Tekeli A, Aljodi M, Civelek A, Arsan S. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg. 2009 Jul-Aug;24(4):404-10. doi: 10.1111/j.1540-8191.2009.00840.x. — View Citation

Ji HW, Ma L, Gao XR, Liu N, Zhang Y, Wang Y, Ma ZX, Wang Y, Wang J, Fu X, Xiong Q, Qi HM. [Establishment of normal reference values for thromboelastography on Chinese population in Beijing]. Zhonghua Yi Xue Za Zhi. 2011 Apr 12;91(14):980-3. Chinese. — View Citation

Pfanner G, Koscielny J, Pernerstorfer T, Gütl M, Perger P, Fries D, Hofmann N, Innerhofer P, Kneifl W, Neuner L, Schöchl H, Kozek-Langenecker SA; Austrian Society for Anaesthesia, Resuscitation and Intensive Care. [Preoperative evaluation of the bleeding history. Recommendations of the working group on perioperative coagulation of the Austrian Society for Anaesthesia, Resuscitation and Intensive Care]. Anaesthesist. 2007 Jun;56(6):604-11. German. — View Citation

Subramanian A, Albert V, Saxena R, Agrawal D, Pandey RM. Establishing a normal reference range for thromboelastography in North Indian healthy volunteers. Indian J Pathol Microbiol. 2014 Jan-Mar;57(1):43-50. doi: 10.4103/0377-4929.130896. — View Citation

Sun W, Jeleniowski K, Zhao X, Shen P, Li D, Hammond JA. Thromboelastography (TEG)-based algorithm reduces blood product utilization in patients undergoing VAD implant. J Card Surg. 2014 Mar;29(2):238-43. — View Citation

Wang SC, Shieh JF, Chang KY, Chu YC, Liu CS, Loong CC, Chan KH, Mandell S, Tsou MY. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc. 2010 Sep;42(7):2590-3. doi: 10.1016/j.transproceed.2010.05.144. — View Citation

Wesley MC, McGowan FX, Castro RA, Dissanayake S, Zurakowski D, Dinardo JA. The effect of milrinone on platelet activation as determined by TEG platelet mapping. Anesth Analg. 2009 May;108(5):1425-9. doi: 10.1213/ane.0b013e3181981fbe. — View Citation

Zambruni A, Thalheimer U, Leandro G, Perry D, Burroughs AK. Thromboelastography with citrated blood: comparability with native blood, stability of citrate storage and effect of repeated sampling. Blood Coagul Fibrinolysis. 2004 Jan;15(1):103-7. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary thromboelastography normal reference values The subjects with normal routine coagulation test results would be included.Thromboelastography was performed by using TEG-5000 TEG-CK (Hemostasis System, USA), and the parameters were recorded. Parameters includes R (coagulation reaction time, initial fibrin formation time), K (Coagulation time), a (a-angle, thrombosis rate), MA (maximum amplitude, absolute agglutination strength of reactive blood clot), LY30 (fibrinolysis rate with 30 min after MA determination) and CI (integrated coagulation index). 2017.6.1-2017.12.1
See also
  Status Clinical Trial Phase
Recruiting NCT01912547 - Thromboelastography During Surgery for Malignant Pleural Mesothelioma Phase 0
Completed NCT03674684 - ROTEM Assessment of Modern Crystalloid, Hydroxyethyl Starch and Gelatin Effect on Coagulation
Recruiting NCT05874843 - Validation of Point-of-care Thromboelastography (TEG 6s) in Pediatric Patients N/A
Withdrawn NCT04705701 - Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care N/A
Not yet recruiting NCT04515420 - The Influence of Noradrenaline on Coagulation and Fibrinolysis in Severe Isolated Brain Injury
Completed NCT01598831 - Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy Phase 3
Completed NCT04580563 - Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study N/A
Withdrawn NCT04274699 - Clinical Evaluation of the Hemosonics Quantra® Coagulation Monitor in Liver and Multivisceral Transplantation
Terminated NCT02540434 - Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions N/A
Completed NCT02203968 - Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST) Phase 1/Phase 2
Unknown status NCT01854476 - Safety and Efficacy Study Comparing Pad-gauze With Anti-fibrinolytic Agent Hemostopan™) to a Regular Pad-gauze Phase 2/Phase 3
Completed NCT00816127 - Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction N/A
Active, not recruiting NCT02926274 - Transfusion Using Stored Whole Blood N/A
Completed NCT05295693 - Quantra vs TEG for Congenital Cardiac Surgery - a Pilot Validation Study
Not yet recruiting NCT04582188 - The Early Coagulopathy for the Prognosis in Sepsis
Recruiting NCT04528888 - Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Phase 3
Recruiting NCT05449834 - Fibrinogen Early In Severe Trauma StudY II Phase 3
Withdrawn NCT04435015 - The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications Phase 1/Phase 2
Not yet recruiting NCT04115722 - Coagulation Parameters in IBD Patients
Completed NCT01228058 - A Prospective Evaluation of Thromboelastography for Identifying Coagulopathy in Severely Injured Patients N/A